Merck's exhibit at #ACC23 in New Orleans (Lei Lei Wu for Endpoints News)
Merck unwraps full PhIII data on the centerpiece from its $11.5B Acceleron buyout: #ACC23
NEW ORLEANS — Merck says sotatercept, Acceleron’s lead drug before the Big Pharma bought it for $11.5 billion, significantly improved scores on an exercise test …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
